Lumida
/CVRX
⌘K
CVRx Inc

CVRx Inc

CVRX
$4.91USD↓-8.91%-0.48 today

MARKET CAP

130.3M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$5 – $5

52W RANGE

$4
$11

AI Summary

Stalk
StalkMedium

Yesterday’s bearish medium-term stance was invalidated by late-June’s F candle and Bullish Pivot Point closing above the 9/21 EMAs, signaling structural repair. CVRX now sits in an early Stage 1 consolidation below the 50 DMA with medium-term bias turned Bullish. Short-term timing is Neutral; execution should be deferred by stalking pullbacks into the 9/21 EMA support or lower consolidation boundary. A decisive close below the 9/21 EMA region would invalidate this bullish posture.

  • ↑Q1 2026 revenue $14.8M (+20% YoY); U.S. heart failure sales $13.7M (+22%).
  • ↑Active implanting centers grew to 257 after expanding sales force.
  • ↓Q1 net loss $13.1M ($0.50/sh) underscores weak profitability.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

CVRx, Inc. (NASDAQ: CVRX) is a medical device company specializing in innovative therapies for heart failure management, prominently featuring its Barostim technology. With a growing market opportunity of nearly 339,000 patients in the U.S. alone, CVRx is pursuing substantial growth avenues within the cardiovascular sector amid evolving reimbursement landscapes. The company stands at the intersection of strategic sales expansion and clinical evidence generation as it endeavors to position Barostim not only as an effective treatment but as a potential standard of care in heart failure therapy.

Bull says

  • ↑Q1 2026 revenue $14.8M (+20% YoY); U.S. heart failure sales $13.7M (+22%).
  • ↑Active implanting centers grew to 257 after expanding sales force.
  • ↑Category 1 CPT codes effective Jan 2026 should improve reimbursements.
  • ↑BenefitHF trial could expand addressable market from 339k to 980k patients.
  • ↑Cash reserves of $72.3M plus debt facility support growth initiatives.
  • ↑Strong liquidity and quality metrics indicate solid short-term financial health.

Bear says

  • ↓Q1 net loss $13.1M ($0.50/sh) underscores weak profitability.
  • ↓Negative earnings yield and low profitability factors signal inefficiencies.
  • ↓Leverage elevated, raising concerns if borrowing costs increase.
  • ↓Medicare Advantage approval rate fell to 46% in Q1 2026.
  • ↓Conservative guidance suggests limited account growth and scalability risks.
  • ↓Size constraints may hinder market presence and long-term expansion.

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-14-2026neutral

Transcript signals

Bull points

  • Yeah, we're feeling good about the guidance that we provided, top line. We're at a point where we believe the MA approval rates at 30 days or even the terminal rates are going to be as good or better than what we've seen in 2025.
  • We delivered a strong start to 2026, exceeding the high end of our guidance range, driven by 22% growth in the United States.
  • This quarter shows early evidence that the foundation we have built is translating into results.

Bear points

  • As far as expectations go for the new center ads on a quarterly basis, we are still setting the expectation for high single digits on a net basis. on a quarter to quarter, but we may see some variability like we did in the first quarter where we were plus five here in the first quarter.
  • the March softening reflects the impact of simultaneous changes in the broader reimbursement environment that are affecting our company and others across the medical device industry.
  • This has resulted in a higher rate of initial denials, particularly in March, on the basis of an experimental designation, even for therapies with established Category 1 codes and well-documented clinical evidence.
Read full transcript analysis ›